Traumatic Brain Injury Market Research Report 2030 | Traumatic Brain Injury Market

Traumatic Brain Injury is defined as a penetrating head injury that disrupts the normal functioning of the brain. It may result when the head suddenly hits an object or when an object pierces the skull and enters brain tissue.


Got queries? Click here and get more insights @ Traumatic Brain Injury Market Landscape

Traumatic Brain Injury Sign and Symptoms

Signs and symptoms may appear directly, within 24 hours, or they'll emerge days or weeks after the injury. Sometimes the symptoms are subtle. An individual may notice a drag but not relate it to the injury. Some people will appear to possess no signs after a TBI, but their condition worsens later. Symptoms modify greatly depending on the severity of the head injury. They'll include any of the following:

●       Headache

●       Paralysis

●       Dilated pupils

●       Vision changes (blurred vision or seeing double)

●       Breathing problems

●       Inappropriate emotional responses

●       Difficulty in speech

●       Difficulty swallowing

●       Body numbness

●       Loss of bladder control

Traumatic Brain Injury Epidemiology Insights

Persons 44 years aged and younger, TBI-related deaths decreased between the periods of 2001–2002 and 2009–2010. Rates for age groups 45–64 years aged remained stable for this same ten-year period.

In the last decade, rates of TBI-related deaths in men decreased from 27.8 to 25.4 per 100,000, and rates in women decreased from 9.6 to 9.0 per 100,000.

Approximately 2.8 million people sustain Traumatic Brain Injury annually within the United States, and each day 153 people die from injuries that include Traumatic Brain Injury.

Traumatic Brain Injury Market Insights

Currently, there is no approved therapy for the treatment of Traumatic Brain Injury. The therapy is based on the injury. Mild traumatic brain injuries usually require no treatment apart from rest and over-the-counter pain relievers to treat a headache. Whereas, Emergency take care of moderate to severe traumatic brain injuries focus on ensuring the person has enough oxygen and an adequate blood supply, maintaining blood pressure and preventing any more extended damage to the head.

Medications available are anti-seizure drugs, coma-inducing drugs, diuretics.

The existing medications being used for those suffering from Traumatic Brain Injury are focused on treating the symptoms and stopping the pain instead of protecting any further damage from occurring.

To overcome this shortcoming of the therapeutic market and to provide better Traumatic Brain Injury treatment options for the moderate to severe TBI patient pool, many molecules are being explored at different levels.

Key pharma players involved in the development of therapies for the Traumatic Brain Injury treatment is Vasopharm GmbH, NeuroVive Pharmaceutical AB, Cellvation, and others.

Request for a sample report @ Traumatic Brain Injury Market Scenario 2030

About DelveInsight 

DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences providing end-to-end comprehensive solutions to improve their performance.  

Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

 

 

 

 

 

 

 

 

Comments

Post a Comment

Popular posts from this blog

Tenosynovial Giant Cell Tumors (TSGCTs) Market Research Report 2030 | Tenosynovial Giant Cell Tumors (TSGCTs) Market

Image
Tenosynovial Giant Cell Tumors   are a type of neoplasm that affects synovial-lined tendon sheaths, synovial joints, and surrounding soft tissue. Locally aggressive benign tissue lesions are defined by synovial lining inflammation in joints and tendons. Overexpression of the colony-stimulating factor 1 receptor is thought to cause these tumors to form. Giant cell tumors of the tendon sheath (GCTTS), pigmented villonodular tumors (PVNTS), extra-articular pigmented villonodular tumors of the tendon sheath, and localized or focal nodular synovitis are all terms used to describe TSGCTs. Tenosynovial Giant Cell Tumors Causes Translocation is an alteration to a chromosome that causes Tenosynovial Giant Cell Tumors. A chromosome segment breaks off and moves around. The cause of these translocations is unknown. The genetic code for making proteins is stored on chromosomes. A protein termed colony-stimulating factor 1 is produced in excess due to the translocation (CSF1). This protein attracts
Read more

Functional Dyspepsia Market Research Report 2030 | Functional Dyspepsia Market

Image
  Functional dyspepsia   is a term for recurring signs and symptoms of indigestion that have no apparent cause. Functional dyspepsia is also called non-ulcer stomach pain or non-ulcer dyspepsia. It's not clear what causes functional dyspepsia. Doctors consider it a functional disorder, which means that routine testing may not show any abnormalities. Hence, it is diagnosed based on symptoms. Functional Dyspepsia Signs and Symptoms  Functional dyspepsia is common and can be long-lasting — although signs and symptoms are mostly intermittent. These signs and symptoms resemble those of an ulcer, discomfort in your upper abdomen, often accompanied by bloating, belching, and nausea, An early feeling of fullness (satiety) when eating, Pain in the stomach that may sometimes occur unrelated to meals, or maybe relieved with meals. Functional Dyspepsia Epidemiology According to an article by Madisch et al. (2018), Functional Dyspepsia is one of the common functional disorders, with a prevalenc
Read more

Fibrodysplasia Ossificans Progressiva Market Research Report 2030 | Fibrodysplasia Ossificans Progressiva Market

Image
  Fibrodysplasia ossificans progressiva   is a disorder in which the skeleton, muscles, and connective tissues, such as tendons and ligaments, are replaced by bone (ossified). This position was to lead to the formation of the bones of the skeleton (extra-skeletal or heterotopic bone) that constrains movement. Fibrodysplasia ossificans progressiva Causes Fibrodysplasia ossificans progressiva is called a mutation in the ACVR1 gene. This gene is involved in bone growth and development. Mutations, and the possibility of a disorderly development. The gene can be inherited from a parent, but in most cases, the, is a new mutation, a person with a less-than-a family history of the disease. As a parent, they have a 50% chance of passing it on to their children. Fibrodysplasia ossificans progressiva Sign and Symptoms The  Fibrodysplasia ossificans progressiva  symptoms begin in the first decade of life with episodes of painful inflammatory soft tissue swellings. Gradually, there occurs restricti
Read more